Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA3038 in Chronic Hepatitis B
NCT06452693Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Sep 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of TQA3038 in Chronic Hepatitis B (CHB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
TQA3038
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06452693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452693.